Trial Profile
A Phase II Study of Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Gemcitabine (Primary)
- Indications Endometrial cancer
- Focus Therapeutic Use
- 01 Nov 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Aug 2013 Planned end date changed from 1 Aug 2014 to 1 Aug 2015 as reported by ClinicalTrials.gov.
- 27 Aug 2012 Planned end date changed from 1 Aug 2012 to 1 Aug 2014 as reported by ClinicalTrials.gov.